These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

681 related items for PubMed ID: 31476489

  • 1. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H, Kim D, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Hwang S, Kim KH, Song GW, Ahn CS, Lee JH, Hwang DW, Kim SC, Jang SJ, Hong SM, Kim TW, Ryoo BY.
    Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
    [Abstract] [Full Text] [Related]

  • 2. Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer.
    Kim H, Kim JY, Park KU.
    Oncology; 2023 Oct; 101(1):41-48. PubMed ID: 36257294
    [Abstract] [Full Text] [Related]

  • 3. Mutational spectrum and precision oncology for biliary tract carcinoma.
    Lin J, Cao Y, Yang X, Li G, Shi Y, Wang D, Long J, Song Y, Mao J, Xie F, Bai Y, Zhang L, Yang X, Wan X, Wang A, Guan M, Zhao L, Hu K, Pan J, Huo L, Lu X, Mao Y, Sang X, Zhang H, Wang K, Wang X, Zhao H.
    Theranostics; 2021 Oct; 11(10):4585-4598. PubMed ID: 33754015
    [Abstract] [Full Text] [Related]

  • 4. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
    Simbolo M, Fassan M, Ruzzenente A, Mafficini A, Wood LD, Corbo V, Melisi D, Malleo G, Vicentini C, Malpeli G, Antonello D, Sperandio N, Capelli P, Tomezzoli A, Iacono C, Lawlor RT, Bassi C, Hruban RH, Guglielmi A, Tortora G, de Braud F, Scarpa A.
    Oncotarget; 2014 May 15; 5(9):2839-52. PubMed ID: 24867389
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R, Li Q, Fu J, Jin Z, Su J, Zhang J, Chen C, Geng Z, Zhang D.
    BMC Cancer; 2021 Feb 03; 21(1):112. PubMed ID: 33535978
    [Abstract] [Full Text] [Related]

  • 10. Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers.
    Zhang W, Shi J, Wang Y, Zhou H, Zhang Z, Han Z, Li G, Yang B, Cao G, Ke Y, Zhang T, Song T, QiangLi.
    Cancer Immunol Immunother; 2021 Apr 03; 70(4):1001-1014. PubMed ID: 33095329
    [Abstract] [Full Text] [Related]

  • 11. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
    Rizzato M, Brignola S, Munari G, Gatti M, Dadduzio V, Borga C, Bergamo F, Pellino A, Angerilli V, Mescoli C, Guido M, Rearden J, Gringeri E, Cillo U, Dei Tos AP, Zagonel V, Loupakis F, Lonardi S, Fassan M.
    Eur J Cancer; 2022 May 03; 166():165-175. PubMed ID: 35303508
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Boerner T, Drill E, Pak LM, Nguyen B, Sigel CS, Doussot A, Shin P, Goldman DA, Gonen M, Allen PJ, Balachandran VP, Cercek A, Harding J, Solit DB, Schultz N, Kundra R, Walch H, D'Angelica MI, DeMatteo RP, Drebin J, Kemeny NE, Kingham TP, Simpson AL, Hechtman JF, Vakiani E, Lowery MA, Ijzermans JNM, Buettner S, Koerkamp BG, Doukas M, Chandwani R, Jarnagin WR.
    Hepatology; 2021 Sep 03; 74(3):1429-1444. PubMed ID: 33765338
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
    Yu H, Xu Y, Gao W, Li M, He J, Deng X, Xing W.
    Front Oncol; 2022 Sep 03; 12():930611. PubMed ID: 36072793
    [Abstract] [Full Text] [Related]

  • 16. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
    Wardell CP, Fujita M, Yamada T, Simbolo M, Fassan M, Karlic R, Polak P, Kim J, Hatanaka Y, Maejima K, Lawlor RT, Nakanishi Y, Mitsuhashi T, Fujimoto A, Furuta M, Ruzzenente A, Conci S, Oosawa A, Sasaki-Oku A, Nakano K, Tanaka H, Yamamoto Y, Michiaki K, Kawakami Y, Aikata H, Ueno M, Hayami S, Gotoh K, Ariizumi SI, Yamamoto M, Yamaue H, Chayama K, Miyano S, Getz G, Scarpa A, Hirano S, Nakamura T, Nakagawa H.
    J Hepatol; 2018 May 03; 68(5):959-969. PubMed ID: 29360550
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Biliary cancer: Utility of next-generation sequencing for clinical management.
    Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J.
    Cancer; 2016 Dec 15; 122(24):3838-3847. PubMed ID: 27622582
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Alterations in DNA Damage Repair Genes in Primary Liver Cancer.
    Lin J, Shi J, Guo H, Yang X, Jiang Y, Long J, Bai Y, Wang D, Yang X, Wan X, Zhang L, Pan J, Hu K, Guan M, Huo L, Sang X, Wang K, Zhao H.
    Clin Cancer Res; 2019 Aug 01; 25(15):4701-4711. PubMed ID: 31068370
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.